Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
Jupiter Neurosciences (JUNS) Form 4 filing: President, Chief Business Officer and Director Alison D. Silva reported three open-market purchases on 01 July 2025 totaling 750 common shares at an average price of roughly $1.03 per share. Following the transactions, Silva directly owns 112,777 shares of JUNS common stock. No derivative security activity was disclosed.
The transactions are coded “P,” indicating routine open-market buys and not part of a Rule 10b5-1 trading plan. While the dollar value is modest (≈ $770), insider buying is generally interpreted as a vote of confidence in the company’s prospects. However, the size of the purchase is immaterial to overall share count and does not meaningfully affect ownership structure.